About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Cardiometabolic Syndrome Could be Treated by Epoxide Hydrolase Inhibition and Thiazolidinediones

by Kathy Jones on April 27, 2013 at 1:45 PM
Font : A-A+

 Cardiometabolic Syndrome Could be Treated by Epoxide Hydrolase Inhibition and Thiazolidinediones

Cardiometabolic syndrome increases the risk for cardiovascular disease in people who are obese and have high blood pressure and also causes significant and rapidly progressive kidney disease.

Scientists at the Medical College of Wisconsin and the University of California at Davis, led by Dr. John Imig and Dr. Bruce Hammock have determined the synergistic actions of inhibiting soluble epoxide hydrolase (sEH) with tAUCB (trans-4-(4-[3-adamantan-1-yl-ureid]-cyclohexyloxy)-benzoic acid) and activating peroxisome proliferator-activator receptorγ (PPARγ) with the thiazolidinedione rosiglitazone on the pathological progression of cardiometabolic syndrome. The findings, which appear in the December 2012 issue of Experimental Biology and Medicine, demonstrate that sEH inhibition and PPARγ activation in combination had the greatest beneficial effects on the multi-disease features and progression of kidney disease associated with cardiometabolic syndrome.

Advertisement

"Inhibitors of sEH have recently reached a point where their ability to combat cardiovascular and kidney diseases can be determined in humans", states Dr. Imig. "In this study we show that when used in combination with a PPARγ agonist therapy for cardiometabolic syndrome that there is a synergistic effect to decrease cardiovascular risk factors and progressive kidney disease. Another potential positive aspect of this combination therapy is that sEH inhibition has beneficial actions to counteract the edema and congestive heart failure that occurs in patients treated long-term with PPARγagonists."

Future studies would include combinational chemistry approaches to design and synthesize drugs with dual sEH inhibitory and PPARγ agonistic activities. Dr. Hammock states, "these approaches are currently being done by his laboratory and others". He also says "that combining sEH inhibition not just with PPARγ but also with other therapies for cardiovascular, inflammatory, and renal diseases are on the horizon and have therapeutic potential as both drug combinations and dual sEH inhibitors with PPARγ activity for treating cardiometabolic syndrome."
Advertisement

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said, " This study by John Imig and Bruce Hammack, performed on spontaneous hypertensive and spontaneous hypertensive obese rat models, suggests that a combined therapy with epoxide hydrolase inhibitors and thiazolidinediones may prove to be efficacious in treatment of the multi-disease characteristics of cardiometabolic syndrome. "



Source: Eurekalert
Advertisement

Advertisement
Advertisement

Latest Heart Disease News

Monday: The Day for Deadly Heart Attacks?
The start of the week is when most fatal heart attacks occur, according to a study.
Delay in Seeking Care Results in 55% of Cardiac Deaths in India
The first community-based study, published in the journal Lancet, says that delays in seeking care account for nearly 55% of the reported cardiac and stroke deaths in India.
The Surprising Impact of Quit Smoking: 36% Lower Cardiovascular Risk
The study emphasizes the existing proof on the heart disease risks of tobacco smoking and the urgent need to stop smoking among cancer survivors.
 Discovering Genetic Risks for Type of Heart Attack Largely Affecting Younger Women
New study findings provide novel pathophysiological insights involving blood vessel integrity and tissue-mediated coagulation in a type of heart attack in young women.
Unlocking the Crystal Ball: Heart Failure Subtypes Helps Forecast Future Risks!
Recent study identifies five heart failure subtypes with the potential for individual patient risk prediction.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Cardiometabolic Syndrome Could be Treated by Epoxide Hydrolase Inhibition and Thiazolidinediones Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests